When psychedelics were first studied more than 50 years ago, researchers noticed that they were useful in helping people explore a greater sense of self. Now, after a half-century hiatus, scientists are studying psychedelics like MDMA, psilocybin, and ketamine as treatment for depression, PTSD, anxiety, and other mental health conditions. So, what promise do they hold as therapeutics? Albert Garcia-Romeu, a researcher at John’s Hopkins University, joins Dr. Sanjay Gupta to talk about how psychedelics can alleviate mental suffering and what the path forward might look like.
To learn more about how CNN protects listener privacy, visit cnn.com/privacy
Learn more about your ad choices. Visit podcastchoices.com/adchoices
The Perfect Storm
In Sickness and in Health
Atlanta Returns to School
Saying Goodbye
One Year Later
Vaccine Hesitancy in Flint, Michigan
So You’re Vaccinated ... Now What?
Instagramming the Pandemic
The Art of Caring
The New 9 to 5
Should the Games Go On?
Olympic Dreams Postponed
The Bumpy Road to Herd Immunity
Good News from Indian Country
Not So Sweet Dreams
The Latest from Wuhan
Covid’s Long Haulers
Honoring a Forgotten Medical Pioneer
Asian Americans are Americans, Too
Are We Still Uncomfortably Numb?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Newscast
Consider This from NPR
What’s That Rash?
The Coronavirus Podcast
Up First